In this paper, we use the four stage DEA method to measure and evaluate the financing efficiency of China's biopharmaceutical industry. Besides that, we analyze the dynamic change trend by using Malmquist index. The research shows that the financing efficiency of China's biomedicine industry has failed to achieve its effectiveness generally. There are much room to improve. And the macro environment and micro environment all affect its financing efficiency in varying degrees. We suggest that government should provide a better financing ecological environment and widening financing channels. At the same time, enterprises themselves should also improve their ability of finds using, in order to improve the total financing efficiency of China's biopharmaceutical industry and make the industry develop more quickly.
Introduction
Biomedical industry as one of the seven strategic emerging industries biological industry subindustry has the characteristics of high technical barriers and large market space. In 2016, the pharmaceutical industry performed well in China's stock market. The total revenue of listed companies increased by 911 billion 600 million, an increase of 17.9%. Among them, the biopharmaceutical sector contributed a lot and has become the investor attention hot spot.
However, the characteristics of this industry, such as large capital demand, long research and development cycle, large investment risk, leading to it's financing situation is not optimistic. At present, domestic scholars mainly focus on analyzing the capital structure, financing strategy or influencing factors of biomedical enterprises. (Wang Yudong, Liang, 2007 [1] ; 2013 [2] ; Chen Xia Jing, adorable, 2017 [3] ) However, there are few researches on the financing efficiency of biomedical enterprises. In fact, one of the important reasons for the difficulty of financing strategic emerging industries, such as biomedicine, is low financing efficiency.(Wang Qiong, Geng Chengxuan, 2017 [4] ) Therefore, this paper will make an empirical analysis on the financing efficiency of biomedical companies in China, exploring the problems and factors of their financing efficiency, and then put forward some suggestions for improvement to promote the healthy and stable development of China's biomedical industry.
Research Design

Evaluation of Model Building
For the evaluation of financing efficiency, Charnes and Rohdes introduced the concept of decisionmaking unit based on frontier production function and put forward the relative efficiency evaluation model in 1978. This method was called Data Envelopment Analysis (DEA), which not only enriched the theory of efficiency evaluation, but also provided a new way to make empirical research on efficiency evaluation [5] . DEA model in the four stages were proposed in this paper by taking DEA as the basic method of the financing efficiency measurement, referring to study of Cao Yu and Geng Chengxuan (2016) and considering the influence of external environmental factors [6] . However, the efficiency result with DEA measurement is static, we can evaluate the financing efficiency dynamically with Malmquist index.
DEA Model Application Procedure in Four Stages.
(1) In the first stage: Measure the financing efficiency of biomedical enterprise by using DEA-BCC model.
Select the input-oriented DEA-BCC model analysis with variable return scale to calculate total loose variable of each input element. The result estimated by DEA-BCC model is taken as comprehensive technical efficiency (TE) value, and this index can be decomposed into scale efficiency (SE) and pure technical efficiency (PTE).
The results measured first stage included the influence of the uncontrolled external environment on financing efficiency, and the influence of external environment on decision-making unit needs to be eliminated in the second stage.
(2)In the second stage: use Tobit regression model to measure the influence of environmental factors.
The result calculated in the first stage can obtain the input loose variable of each input index except for the efficiency value. As the input loose variable is at least zero, it will lead to the data truncation. Therefore, Tobit model is selected to analyze the input loose variable and exogenous environmental variable measured in the first stage, namely the relationship between external influencing factors in this paper. Thus, the regression model is built as shown below by taking total loose variable of each decision-making unit as explained variable, and using external environment factor as explanatory variable.
Of which S ij represents total loose variable of the ith input term in the jth decision-making unit; Z ij represents a variable of the environmental factor; β i represents a factor to be evaluated; μ ij represents the error term.
(3) In the third stage: Adjust the initial input data Analyze the regression results of Tobit model in the second stage and adjust the original input data as following:
Of which when i=1, 2, 3……M, X aij represents the input term of the ith term after adjustment; Max｛Ŝ ij ｝represents the worst environmental factor level; Max｛Ŝ ij ｝-Ŝ ij represents the difference in input due to different environmental factors. After the adjustment, all decision-making units will be placed in the worst external environment for uniform measurement to eliminate the deviation of measurement results caused by external environmental factors.
(4) In the fourth stage: use the adjusted data to re-measure the efficiency of biomedical enterprise DEA-BCC calculation was carried out by applying the adjusted input amount and initial output volume in the fourth stage. The influence of environmental factors on efficiency will be eliminated by efficiency measurement on this occasion.
Malmquist Index Model. Malmquist index can be used to calculate efficiency in different periods and the trend change, which was proposed by Farell in 1957[8]. The distance function Dt (Xt, Yt) is used to calculate productivity index in the Malmquist index method, and of which t and t+1represent two consecutive periods respectively. Malmquist index is expressed as:
(X t , Y t ) and (X t+1 , Y t+1 ) represent the input-output collections. Distance functions D t (X t , Y t ) is similar to in the efficiency value of input-oriented DEA model, and Malmquist index can reflect the efficiency change of decision-making units in the two consecutive years. Malmquist index also can be decomposed into technical change and efficiency change.
is the change in technical efficiency for two consecutive years and the change of relative technical efficiency (EC).
is the change in technological innovation and other factors for two consecutive years and the change of technical progress (TC).
When EC >1, it indicates that the technical efficiency has been improved, which reflects the improvement of production and management level of decision-making unit; when EC<1, it indicates that the efficiency has decreased; when TC >1, it indicates that technical progress has made; when TC<1, it indicates that the technology has not changed. In the DEA model with variable return scale, Technical efficiency change can be decomposed into pure technical efficiency index and scale efficiency index, namely EC=PEC×SEC. When PEC is greater than 1, it shows that the efficiency has been improved; when PEC less than 1, it shows that there is a decline in efficiency. SEC represents the change trend of scale efficiency.
Evaluation of Index System Design
Input Index. (1) Asset-liability ratio
Asset-liability ratio is the proportion of total liabilities to total assets in enterprise, which can reflect the capital structure and financing structure of enterprises. Selection of this index as input index can not only inspect the financing structure, but also be seen that the ability to use debt financing for operation.
(2) Operating cost Most of the funds incorporated are invested in the actual production operation, so the level of operating cost will affect the final profit level of enterprise and financing efficiency. The main business cost is used to measure the operating cost.
(3) Employee benefits payable Employee benefits payable can reflect the enterprise's investment in human capital, As the knowledge concentrated industry, the investment of human capital in biology medicine industry is related to technical level and management level. For this, this paper tries to include this index into the evaluation system to consider the impact of human capital investment on financing efficiency.
Output Index. (1) Net margin Net profit can directly reflect business performance of the enterprise, and whether the funds invested are used effectively can be reflected through this index. So the net margin is selected as the output index of financing efficiency.
(2) Return on equity Return on equity = net margin/owner's equity, which reflects the income level of shareholders' equity. It can measure the efficiency of the enterprise's own funds, and reflect profit level and income situation. The higher the return on equity; the better the management efficiency of enterprise, and the easier financing in the capital market will be.
Sample Selection and Data Source
Listed companies in the biology medicine sector of Shanghai and Shenzhen were chosen as analysis samples, and the sample period was from 2013 to 2016. ST companies were eliminated from samples, and finally 46 listed companies in biology medicine industry are selected. Among them, there are 33 companies in the eastern region, 8 companies in the central region and 5 companies in the eastern region.
Empirical Analysis
Descriptive Statistical Analysis of Samples
Descriptive statistics of business data of 46 biomedical enterprises from 2013 to 2016 were presented in this paper, and the statistical result was shown in Table 1 below. From the statistical results, it was observed that the scale and operating indicators of enterprises varied greatly. It could be seen that most enterprise capital structure was reasonable. While it showed that there was a big difference between enterprises form the index of net margin. In addition, there has been no significant change in the concentration ratio of enterprises' shareholding right, which indicated that there is no significant difference in most of enterprises' ownership structure. 
Empirical Measurement Result Analysis
DEA Model Measurement Result Analysis of Biology Medicine Industry in Four Stages.
According to the calculation results of the financing efficiency of 46 listed biomedical in 2016 in the first stage, the statistics were summarized in Table 2 and 3: Table 2 shows that only 7 companies have effective DEA; 10 companies have DEA efficiency; the rest have DEA inefficiency. The average value of overall efficiency, technical efficiency and scale efficiency were 0.752, 0.795 and 0.943 respectively, which showed that the overall level of financing efficiency was relative low. According to Table 3 , it can be observed that the efficiency in the eastern region was lower, which reflected that the number of biomedical enterprise was less in the western region, but it has a high quality.
(2) The impact of environmental factors on relaxation.
As environmental factors can affect the measurement results of financing efficiency, Tobit model is used for the regression analysis of panel data in this paper by taking loose variable of inputs calculated in the first stage as the dependent variable, and using economic development level (GDP of the province where the company is located), industrial structure (the ratio of the second industry) and the development degree of capital market (regional financing scale) independent variable. The specific results are shown in Table 4 . Table 4 . Tobit regression results for slack.
Variable
Operating cost Employee benefits payable Assets and liabilities Constant term 2.4879*** 1.4731*** 1.9070 ** Economic level 0.0073 0.0013 0.0181* Industrial structure 0.0118 0.0787 0.3214** Capital market development -0.1196** -0.06809** -0.1094*** (Note: "***", "**" and "*" are significant at the level of 1%, 5% and 10% respectively.) According to Table 4 , it can be seen that the economic level and industrial structure both have a significant positive impact on loose variable of asset-liability ratio, which shows that enterprises more tend to operate in debt in developed cities and relatively developed secondary industry. The capital market development degree has a negative effect on loose variable of operating cost input, loose variable of employee benefits payable and loose variable of asset-liability ratio input, which shows that enterprise management level is higher in the more developed capital markets due to the lower waste of operating and manpower cost with better asset structure.
(3) The results of BCC model measurement after elimination of environmental variables influence In the fourth stage, according to the result of Tobit regression analysis, the initial input variable was adjusted by using the modified formula to measure the financing efficiency . The result is shown as follows. By comparing the results, it shows that the mean value of efficiency has risen from 0.752 to 0.822, which rose by 8.52% after elimination of environmental factors. The mean value of technical efficiency has increased from 0.795 to 0.873, which rose by 8.93%. The average scale efficiency has decreased from 0.943 to 0.939, which declined 0.43%.After elimination of the impact of environmental factors, the enterprise has been improved the efficiency, the result is more accurate. So the scale efficiency is an important factor hindering the improvement of financing efficiency.
Dynamic Analysis of Financing Efficiency in Biology Medicine Industry. The measure above was just a static analysis, which could not reflect the dynamic changes. Then DEAP2.1 software was used for Malmquist index analysis of the financing efficiency. The measurement results are shown in Table 5 below. As shown in Table 5 , Malmquist index of enterprises in 2013-2014 is less than 1, which indicates that the financing efficiency has fallen. By decomposition, both the technical efficiency index and scale efficiency index were less than 1. Besides, Malmquist index in 2014-2015 was less than 1. Through decomposition, the pure technical efficiency was greater than 1. By 2016, the total factor productivity was greater than 1, the financing efficiency increased. The specific analysis showed that the pure technical efficiency index was less than 1 that in 2015-2016 while the scale efficiency index was greater than 1. It was the progress of scale efficiency that contributed to the progress of total factor productivity.
In general, from the static level, few listed biomedical enterprises in 2016 have reached a high financing efficiency. While from the dynamic level, the overall financing efficiency experienced the variation trend of decreasing and then increasing. The improvement of technical efficiency and scale efficiency promote the financing efficiency.
Analysis of Influencing Factors of Financing Efficiency in Biology Medicine Industry.
(1) Variable selection In the second stage of DEA model, the influence of external macro-environmental factors has been analyzed, but the macro-factors are uncontrollable. It is also the micro environment of enterprises that affects financing efficiency. For this, efficiency value adjusted in the fourth stage is used as the index of the financing efficiency in this paper to analyze the influence of enterprise micro factors on the financing efficiency. The specific index is shown in Table 6 below: (2) Model building and regression analysis According to the financing efficiency and influencing factors, the multiple regression models are built as follows: Y=β 0 +β 1 X 1 +β 2 X 2 +β 3 X 3 +β 4 X 4 +μ (5) Of which β 0 is constant term; β 1 , β 2 , β 3 and β 4 represent correlation coefficient; μ is random disturbance term. Tobit regression is carried out. The results are shown below: 0.125602 -0.97335 0.3304 (Note: "***", "**" and "*" are significant at the level of 1%, 5% and 10% respectively.)
(3) Analysis of the empirical results of influencing factors Firstly, the asset scale of enterprise has a significant negative correlation with the financing efficiency. Enterprises should not blindly expand the scale, we should pay attention to the improvement of management level.
Secondly, there is a positive correlation between growth ability and financing efficiency, The better the development prospects, the higher the financing efficiency will be.
Thirdly, liabilities level negatively affects financing efficiency. Enterprises that choose more debt financing need to reserve funds for non-callable bond, which can lead to the waste of funds and lower financing efficiency. Enterprises should control the debt scale and broaden the financing way.
Fourthly, there is no significant impact on ownership concentration and financing efficiency. Enterprises can control their own ownership structure reasonably.
Conclusion and Suggestion
46 biomedical enterprises in A-share companies are taken as samples to analyze the financing efficiency in 2016 as well as the evolution trend of financing efficiency from 2013 to 2016, and the influence of internal and external environmental factors on financing efficiency by using DEA-BCC model and Malmquist index method. The following conclusion is drawn:
(1) From static perspective, in 2016, only 7 companies have reached DEA efficiency. Generally speaking, the optimal effects of enterprise production have not been given full play.
(2) From dynamic perspective, Malmquist index experienced the process of decreasing firstly and then increasing from 2013 to 2016. The main reason is technical efficiency and scale efficiency was improved, and the productivity growth of total factors was limited.
(3) In the external environmental factors, economic development, industrial structure as well as capital market development have different influence on financing efficiency of enterprises, and enterprise scale, capital structure and growth ability are closely related to the financing efficiency.
Biomedical enterprises should strengthen and improve the system construction; enhance level of operation and management; control enterprise scale reasonably; promote profitability; plan financing structure rationally; increase technical innovation level and use various financing channels. The government shall reinforce the construction of financial markets and promote coordinated development of regions to form scale effect, create a good science and technology atmosphere and lead science and technology investment.
